Global Dementia And Movement Disorders Market To Generate Revenue Of USD 7.45 Billion By 2028

The global dementia and movement disorders market size is estimated to grow to about USD 7.45 billion by 2028, with a compound annual growth rate (CAGR) of approximately 6.5 percent over the forecast period.

A set of symptoms that substantially impair memory, reasoning, and social skills are referred to be dementia when they significantly interfere with day-to-day functioning. Although there isn't one particular disease that causes dementia, many diseases can. There are several different disorders known as movement disorders that cause anomalies in the motor system. These include Huntington's disease, Wilson disease, dystonia, tremors, Parkinson's disease, and other Parkinsonian disorders.

The outbreak of Covid-19 had a moderate effect on global dementia and movement disorders market. In the initial phase of 2020, the market growth was hampered owing to strict rules & regulations imposed by the government to curb the spread of the disease. In addition to this, lockdown across the countries disrupted the supply chain and distribution chain which affected the operations of key players. However, with ease in restrictions, the market is expected to grow at a healthy growth rate during the forecast period.

The treatment of diverse mental problems across the world's population is benefiting from the fast-increasing technical breakthroughs and treatment methods in mental health care. These developments have led to improved methods of treating dementia and mobility abnormalities. The growing understanding of mental health may be a key growth indicator for the management of dementia and mobility disorders. Also, global dementia and movement disorders market is being expanded by the competitors through partnerships, joint ventures, acquisitions, and mergers. In addition to this, the players may be able to establish their dominance in the field of treatment by a partnership with pharmaceutical firms to create effective medications for the treatment of neurodegenerative diseases. Furthermore, increasing focus on the development of new drugs for the effective treatment of dementia and movement disorders is likely to create numerous opportunities for the market during the forecast period. However, high prices associated with the treatment of dementia and movement disorders and lack of awareness among the people in rural countries are some of the factors that may limit the growth of the market.

The global dementia and movement disorders market is categorized based on drug class, type, route of administration, end-use, and region. Glutamate inhibitors, acetylcholinesterase inhibitors, MAO inhibitors, and others are included in the drug class segment. Based on the type, the market is fragmented into progressive dementia, movement disorder, and other neurological abnormalities. The route of administration market comprises parenteral and oral. The end-use segment is classified into hospitals, clinics, and others.

Geographically, North America is estimated to account for a maximum share of 48% in global dementia and movement disorders market during the forecast period. Factors such as the growing geriatric population, rapid adoption of advanced technologies in healthcare, and huge investments in R&D activities for the drug discovery & development programs are fostering the market growth in this region. Europe is also expected to contribute a significant share of the market. On the other hand, the market in Asia Pacific is predicted to grow at the highest CAGR value during the forecast period due to government financial backing for enhancing quality healthcare infrastructure in numerous countries throughout the region and the intensifying campaigns for promoting consciousness of the therapies for dementia and movement disorders.

Novartis AG, Merck and Co. Inc., Biogen Inc., Bausch Health Companies Inc., Acorda Therapeutics Inc., AbbVie Inc., Johnson and Johnson, GlaxoSmithKline Plc, Eisai Co. Ltd., and Teva Pharmaceutical Industries Ltd. are some of the major players operating in global dementia and movement disorders market.

Recent developments:

• In January 2020, Biogen revealed the acquisition of a new therapeutic asset with potential use in treating Parkinson's and Alzheimer's diseases.
• In October 2021, Teva Pharmaceutical Industries Ltd. and MODAG GmbH proclaimed a strategic partnership for the exclusive license and development of MODAG's main neurodegenerative disease drug candidate anle138b and a related molecule, sery433, on a global scale.

Browse the full “Dementia and Movement Disorders Market By Type (Progressive Dementia, Movement Disorder, and Other Neurological Abnormalities), By Drug Class, (Glutamate inhibitors, acetylcholinesterase inhibitors, MAO inhibitors, and Others), By Route of Administration (Parenteral and Oral), By End-Use (Hospitals, Clinics, and Others), By Region – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028.” Report at https://www.zionmarketresearch.com/report/dementia-movement-disorders-market

Global dementia and movement disorders market is segmented as follows:

By Type

• Progressive Dementia
• Movement Disorder
• Other Neurological Abnormalities

By Application

• Glutamate inhibitors
• Acetylcholinesterase inhibitors
• MAO inhibitors
• Others

By Route of Administration

• Parenteral
• Oral

By End User

• Hospitals
  • Clinics
  • Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com